Notice of patent registration for the stem cell gene therapy technology SR-GT1 related to treatment for nutritional epidermolysis bullosa completed in Korea. Disclosure of basic information such as invention title, jurisdiction, application number, and applicant.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4599","jir_company_name":"StemRIM","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4599-20260708-01.pdf","jir_short_summary":"Notice of patent registration for the stem cell gene therapy technology SR-GT1 related to treatment for nutritional epidermolysis bullosa completed in Korea. Disclosure of basic information such as invention title, jurisdiction, application number, and applicant.","jir_summary":"### Section Heading\nThis is an announcement regarding patent registration related to StemRIM's stem cell gene therapy technology 'SR-GT1.' It reports completion of patent registration in Korea and lists basic information such as the invention title, filing jurisdiction, registration number, and applicant. The patent registration may influence future business strategy and R&D progress. Note that there are no financial figures, dividends, or capital policy details in the body.\n\n### Second Section Heading\nAs a forward-looking view, the patent registration of SR-GT1 could impact moves toward clinical application, expansion of filings in other regions, and potential funding for research and development. The announcement includes technical and legal information such as applicant, registration number, invention title, and filing date, which investors should monitor for technological progress and IP strengthening.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#StemRIM, #PatentRegistration, #Korea","jir_key_figures":"Patent Registration Announcement (Korea)\nInvention title: Therapeutic Agent \/ Technique for Nutritional Epidermolysis Bullosa (SR-GT1)\nJurisdiction: Korea","jir_meta_title":"\u3010StemRIM\u3011SR-GT1 Patent Registration Notice | Korea","jir_meta_description":"Notice of patent registration for SR-GT1, StemRIM's stem cell gene therapy technology, in Korea. Disclosure of basic information such as invention title, jurisdiction, and registration number. No financial data provided.","jir_og_title":"StemRIM SR-GT1 Patent Registration Notice","jir_og_description":"Publication of Korea patent registration for StemRIM's stem cell gene therapy technology SR-GT1, focusing on technical and IP information.","jir_og_image_url":"\/assets\/og\/company-product_announcement.jpg","jir_chart_data_collection":"[]","ir_related_company":58113,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-77300","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n